{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:07:55Z","timestamp":1790798875472,"version":"4.1.0"},"reference-count":9,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.1001\/jamadermatol.2021.5476","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T16:04:00Z","timestamp":1642003440000},"page":"189","source":"Crossref","is-referenced-by-count":135,"title":["Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti\u2013Programmed Cell Death 1 and Anti\u2013Programmed Cell Death Ligand 1 Therapy"],"prefix":"10.1001","volume":"158","author":[{"given":"Kimberly","family":"Tang","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Department of Dermatology, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayhyun","family":"Seo","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Dermatology, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce C.","family":"Tiu","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Dermatology, Boston"},{"name":"Harvard Medical School, Department of Dermatology, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Le","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Department of Dermatology, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vartan","family":"Pahalyants","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Dermatology, Boston"},{"name":"Harvard Medical School, Department of Dermatology, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel S.","family":"Raval","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Dermatology, Boston"},{"name":"Harvard Medical School, Department of Dermatology, Boston, Massachusetts"},{"name":"Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl O.","family":"Ugwu-Dike","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Dermatology, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Zubiri","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Medicine, Division of Oncology, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Naranbhai","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Medicine, Division of Oncology, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Carrington","sequence":"additional","affiliation":[{"name":"Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland"},{"name":"Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge"},{"name":"Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Department of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Medicine, Division of Oncology, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Department of Dermatology, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam M.","family":"Asgari","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Dermatology, Boston"},{"name":"Harvard Medical School, Department of Dermatology, Boston, Massachusetts"},{"name":"Department of Population Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Department of Dermatology, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Dermatology, Boston"},{"name":"Harvard Medical School, Department of Dermatology, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"dbr210025r1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs.","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"dbr210025r2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"17","key":"dbr210025r3","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"30","key":"dbr210025r4","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events.","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"dbr210025r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"issue":"8","key":"dbr210025r6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.annonc.2021.05.357","article-title":"The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients.","volume":"32","author":"Street","year":"2021","journal-title":"Ann Oncol"},{"key":"dbr210025r7","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis.","author":"Wongvibulsin","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"dbr210025r8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001935","article-title":"Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.","volume":"9","author":"Kalinich","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"dbr210025r9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer.","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2787886\/jamadermatology_tang_2022_br_210025_1643827859.16208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T16:05:29Z","timestamp":1645027529000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2787886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.5476","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}